The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
Open accessAbstract
PURPOSE: Total neoadjuvant therapy is a new paradigm for rectal cancer treatment. Optimal scheduling of preoperative chemoradiotherapy (CRT) and chemotherapy remains to be established. PATIENTS AND METHODS: We conducted a multicenter, randomized, phase II trial using a pick-the-winner design on the basis of the hypothesis of an increased pathologic complete response (pCR) of 25% after total neoadjuvant therapy compared with standard 15% after preoperative CRT. Patients with stage II or III rectal cancer were assigned to group A for induction chemotherapy using three cycles of fluorouracil, leucovorin, and oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy) or to group B for consolidation chemotherapy after CRT. Secondary end points included toxicity, compliance, and surgical morbidity. RESULTS: Of the 311 patients enrolled, 306 patients were evaluable (156 in group A and 150 in group B). CRT-related grade 3 or 4 toxicity was lower (37% v 27%) and compliance with CRT higher in group B (91%, 78%, and 76% v 97%, 87%, and 93% received full-dose radiotherapy, concomitant fluorouracil, and concomitant oxaliplatin in groups A and B, respectively); 92% versus 85% completed all induction/consolidation chemotherapy cycles, respectively. The longer interval between completion of CRT and surgery in group B (median 90 v 45 days in group A) did not increase surgical morbidity. A pCR in the intention-to-treat population was achieved in 17% in group A and in 25% in group B. Thus, only group B ( P < .001), but not group A ( P = .210), fulfilled the predefined statistical hypothesis. CONCLUSION: Up-front CRT followed by chemotherapy resulted in better compliance with CRT but worse compliance with chemotherapy compared with group A. Long-term follow-up will assess whether improved pCR in group B translates to better oncologic outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience
Clavien, P. A., Barkun, J., de Oliveira, M. L., Vauthey, J. N., Dindo, D., Schulick, R. D., de Santibañes, E., Pekolj, J., Slankamenac, K., Bassi, C., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b13ca2 · Cited by 11,482
Sauer, R., Liersch, T., Merkel, S., Fietkau, R., Hohenberger, W., Hess, C., Becker, H., Raab, H.-R., Villanueva, M.-T., Witzigmann, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1836 · Cited by 2,095
Self-citationMaas, M., Nelemans, P. J., Valentini, V., Das, P., Rödel, C., Kuo, L.-J., Calvo, F. A., García-Aguilar, J., Glynne-Jones, R., Haustermans, K., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70172-8 · Cited by 1,945
Self-citationvan Gijn, W., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. M.-K., Putter, H., Wiggers, T., Rutten, H. J., Påhlman, L., Glimelius, B., & van de Velde, C. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70097-3 · Cited by 1,888
Duration of adjuvant chemotherapy for stage III colon cancer
Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713709 · Cited by 1,092
Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Stojanovic-Rundic, S., Bensadoun, R.-J., Bardet, E., Beny, A., Ollier, J.-C., Bolla, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70599-0 · Cited by 730
Rödel, C., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R.-D., Ghadimi, M., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 726
Self-citationGarcia-Aguilar, J., Chow, O. S., Smith, D. D., Marcet, J. E., Cataldo, P. A., Varma, M. G., Kumar, A. S., Oommen, S., Coutsoftides, T., Hunt, S. R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00004-2 · Cited by 697
Rödel, C., Liersch, T., Becker, H., Fietkau, R., Hohenberger, W., Hothorn, T., Graeven, U., Arnold, D., Lang-Welzenbach, M., Raab, H.-R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70187-0 · Cited by 696
Self-citationAdoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Cercek, A., Roxburgh, C. S. D., Strombom, P., Smith, J. J., Temple, L. K. F., Nash, G. M., Guillem, J. G., Paty, P. B., Yaeger, R., Stadler, Z. K., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0071 · Cited by 650
Cited by
Feng, L., Liu, Z., Li, C., Li, Z., Lou, X., Shao, L., Wang, Y., Huang, Y., Chen, H., Pang, X., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00215-6 · Cited by 339
Zhang, H., Li, S., Jin, X., Wu, X., Zhang, Z., Shen, L., Wan, J., Wang, Y., Wang, Y., Yang, W., et al. (2022) · Radiation Oncology · doi:10.1186/s13014-022-02031-4 · Cited by 12
Metadata
- Authors
- Fokas, E., Allgäuer, M., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., Schmiegel, W., Jacobasch, L., Weitz, J., Folprecht, G., Schlenska-Lange, A., Flentje, M., Germer, C.-T., Grützmann, R., Schwarzbach, M., Paolucci, V., Bechstein, W. O., Friede, T., Ghadimi, M., Hofheinz, R.-D., Rödel, C., & on behalf of the German Rectal Cancer Study Group
- Venue
- Journal of Clinical Oncology
- Published
- 2019-12-01
- Volume
- 37
- Issue
- 34
- Pages
- 3212-3222
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2947040388
- Cited by
- 549
- References
- 26
- FWCI
- 22.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. https://app.cochat.ai/papers/10.1200/jco.19.00308
- The paper
- Fokas, E., Allgäuer, M., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., Schmiegel, W., Jacobasch, L., Weitz, J., Folprecht, G., Schlenska-Lange, A., Flentje, M., Germer, C.-T., Grützmann, R., Schwarzbach, M., . . . on behalf of the German Rectal Cancer Study Group. (2019). Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.00308
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
